Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors
2023-508572-11-00Phase 3Authorised
- Sponsor
- Region Skåne
- Start
- Oct 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lutetium Lu 177-edotreotide in neuroendocrine tumour (NET) (2 arms), sponsored by Region Skåne. Primary endpoint: Median progression-free survival (PFS). Planned start Oct 2024; status: authorised.
02
Drugs
lutetium Lu 177-edotreotide
03
Conditions
neuroendocrine tumour (NET)
Beyond the preview
Go deeper on 2023-508572-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508572-11-00.